What Clinicians Want to Know: Addressing Community Oncologists’ Questions About the Roles of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma

Faculty

Faculty

Joshua Brody

MD

The Tisch Cancer Institute at Mount Sinai, New York, New York

Director, Lymphoma Immunotherapy Program

Icahn School of Medicine at Mount Sinai, New York, New York

Faculty Member, Icahn Genomics Institute

Faculty

Manali Kamdar

MD, MBBS

University of Colorado Cancer Center Aurora, Colorado

Associate Professor Clinical Director of Lymphoma Services Morton and Sandra Saffer Endowed Chair in Hematology Research Division of Hematology, Hematologic Malignancies

Faculty

Jason Westin

MD, MS

The University of Texas MD Anderson Cancer Center Houston, Texas

Director, Lymphoma Clinical Research Section Chief, Aggressive Lymphoma Professor, Department of Lymphoma and Myeloma

Moderator

Jeremy S Abramson

MD, MMSc

Massachusetts General Hospital, Boston, Massachusetts

Director, Center for Lymphoma

Harvard Medical School, Boston, Massachusetts

Professor of Medicine

Additional faculty to be announced.

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL)

• Factors such as patient age, performance status, comorbidities or prior therapies influencing eligibility for CAR T-cell therapy
• Long-term efficacy and safety data with axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tis-cel) and lisocabtagene maraleucel (liso-cel) for multiregimen-relapsed DLBCL
• Major findings from Phase III studies with CAR T-cell therapy as second-line treatment for DLBCL
• FDA approvals of axi-cel and liso-cel as second-line therapy, and appropriate identification of candidates for this strategy
• Rationale for, preliminary results with and ongoing assessment of CAR T-cell therapy in the up-front setting for high-risk disease
• Early results with and ongoing investigation of other CAR T-cell platforms for DLBCL (eg, rapcabtagene autoleucel)

MODULE 2: Bispecific Antibody Therapy for DLBCL

• Pharmacologic similarities and differences among the various approved and investigational CD20 x CD3 bispecific antibodies for non-Hodgkin lymphoma (NHL)
• Key efficacy and safety outcomes from pivotal studies of glofitamab and epcoritamab monotherapy for relapsed/refractory (R/R) DLBCL
• FDA approvals of glofitamab and epcoritamab; evidence-based sequencing of and selection between these agents for R/R DLBCL
• Published data with and potential role of odronextamab monotherapy for R/R DLBCL
• Available Phase III findings with bispecific antibodies in combination with other anticancer therapies and in earlier settings for DLBCL, including those from STARGLO, SUNMO and Part 1 of the OLYMPIA-3 study
• Early data with and ongoing assessment of other bispecific antibody-containing combination strategies for DLBCL

MODULE 3: CAR T-Cell Therapy for Other Lymphoma Subtypes

• Extended follow-up with axi-cel, tis-cel and liso-cel for multiregimen-relapsed follicular lymphoma (FL); appropriate selection of candidates with FL for CAR T-cell therapy
• Outcomes from the high-risk second-line subgroup of the Phase II TRANSCEND FL study of liso-cel for R/R FL; implications, if any, for therapeutic sequencing
• Ongoing and planned trials (eg, ZUMA-22, LEDA, TRANSFORM FL) of CAR T-cell therapy for R/R FL
• Key clinical research findings with brexucabtagene autoleucel and liso-cel for R/R mantle cell lymphoma (MCL)
• Optimal integration of CAR T-cell therapy into current MCL treatment algorithms
• Published results with liso-cel for R/R marginal zone lymphoma (MZL); FDA priority review status and potential clinical role

MODULE 4: Bispecific Antibody Therapy for FL and Other Lymphoma Subtypes

• Available data establishing the efficacy and safety of mosunetuzumab and epcoritamab monotherapy for R/R FL
• FDA approval of mosunetuzumab and epcoritamab monotherapy for FL after 2 or more lines of systemic therapy; optimal incorporation opposite other available treatment options
• Published data with odronextamab monotherapy for R/R FL from the ELM-1 and ELM-2 trials
• Ongoing FDA review of odronextamab monotherapy for R/R FL; potential clinical role
• Emerging outcomes from the Phase III EPCORE FL-1 study supporting the recent FDA approval of epcoritamab in combination with lenalidomide and rituximab for R/R FL; selection of patients appropriate for this approach
• Available research findings with other bispecific antibody-based combination regimens for FL, including in the first-line setting
• Available data with, ongoing investigation of and potential clinical role of bispecific antibodies for other NHL subtypes (eg, MCL, MZL)

MODULE 5: Tolerability Considerations with CAR T-Cell Therapy and Bispecific Antibodies

• Comparative frequency and severity of cytokine release syndrome (CRS) and neurotoxicity/immune effector cell-associated neurotoxicity syndrome (ICANS) with available anti-CD19 CAR T-cell constructs for various NHL subtypes
• Guideline-endorsed approaches for the mitigation, monitoring and management of CRS and neurotoxicity/ICANS; role of corticosteroids, tocilizumab and other supportive care interventions
• Rationale for and potential implications of the recent elimination of the Risk Evaluation and Mitigation Strategy for patients receiving CAR T-cell therapy
• Long-term tolerability and toxicity considerations (eg, delayed neurotoxicity, cytopenias, hypogammaglobulinemia, infection, secondary malignancy) with CAR T-cell therapy
• Incidence, severity and time course of CRS and neurotoxicity/ICANS with bispecific antibody therapy for NHL
• Other tolerability concerns with bispecific antibodies for NHL; recommended mitigation and management protocols

Target Audience
This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Develop an understanding of the biological rationale for the development of CD19-directed chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells in patients with various forms of non-Hodgkin lymphoma (NHL).
• Appraise the scientific justification for the evaluation of CD20 x CD3 bispecific antibodies for patients with various forms of NHL, and assess the similarities and differences among currently available agents in this class.
• Evaluate the available clinical research database with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies in the management of relapsed/refractory diffuse large B-cell lymphoma, and optimally incorporate these approaches into current treatment algorithms.
• Assess available research findings with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies for other B-cell lymphomas, including follicular lymphoma and mantle cell lymphoma, and identify patients for whom these novel approaches should be considered or recommended.
• Recognize adverse events associated with available and investigational CAR T-cell therapies and bispecific antibodies, and implement strategies to educate patients and manage complications.
• Recall ongoing research attempting to further define the optimal role of CAR T-cell therapy and bispecific antibody-based strategies for NHL, and counsel patients about potential clinical trial participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — Dr Brody has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Kamdar — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group. Dr Westin — Advisory Committees: Genentech, a member of the Roche Group, Kite, A Gilead Company, Novartis; Consulting Agreements: AbbVie Inc, ADC Therapeutics, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Novartis, Nurix Therapeutics Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc; Contracted Research: ADC Therapeutics, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Novartis, Nurix Therapeutics Inc, Regeneron Pharmaceuticals Inc. Additional faculty to be announced.

MODERATOR
Dr Abramson — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Celgene Corporation, Foresight Diagnostics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Interius BioTherapeutics, Miltenyi Biotec, Novartis, Roche Laboratories Inc, Seagen Inc; Contracted Research: Bristol Myers Squibb, Celgene Corporation, Cellectis, Genentech, a member of the Roche Group, Merck, Mustang Bio, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, Genentech, a member of the Roche Group, and Genmab US Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room C (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.